Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cemiplimab

(seh-MIP-lih-mab)
A drug that binds to the protein PD-1 to help immune cells kill cancer cells better and is used to treat different types of cancer. Cemiplimab is used to treat certain types of basal cell carcinoma and cutaneous squamous cell carcinoma (types of skin cancer) that are locally advanced or have spread to other parts of the body. It is also used alone or with other drugs to treat adults with non-small cell lung cancer that is locally advanced or has spread to other parts of the body and may have the PD-L1 protein, but does not have a mutation (change) in the EGFR, ALK, or ROS1 gene. It is also being studied in the treatment of other types of cancer. Cemiplimab may block PD-1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Libtayo.
More Information
Search NCI's Dictionary of Cancer Terms